Skip to main content

1093.HK

Equity

CSPC PHARMA

Health Care · Drug Manufacturers - General

$9.60

+9.60 (+0.00%)

Open

N/A

Day Range

$9.57 - $9.63

52W Range

$4.55 - $11.63

Volume

212K

Price History

Key Statistics

Market Cap

N/A

P/E Ratio

N/A

EPS

N/A

Dividend Yield

N/A

P/B Ratio

N/A

Payout Ratio

N/A

ROE

N/A

Debt/Equity

N/A

Peers in Health Care

Symbol Name Price Mkt Cap Div Yield Change
ACAD ACADIA Pharmaceuticals Inc. $22.81 N/A - +0.00%
AKBA Akebia Therapeutics, Inc. $1.26 N/A - +0.00%
ABBV AbbVie Inc. $234.26 N/A 2.84% +0.00%
AGEN Agenus Inc. $3.34 N/A - +0.00%
ACB Aurora Cannabis Inc. $3.71 N/A - +0.00%
CRSP CRISPR Therapeutics AG $60.77 N/A - +0.00%
001540.KQ AHN-GOOK PHA $8,070.00 N/A 5.45% +0.00%
A Agilent Technologies, Inc. $118.17 N/A 0.85% +0.00%

Community Sentiment

Sign in to vote

0% Bullish 0% Neutral 100% Bearish

0 votes

Discussion (0)

Sign in to join the discussion

Loading comments...

About CSPC PHARMA

CSPC Pharmaceutical Group Limited, an investment holding company, engages in the manufacture and sale of pharmaceutical products in Mainland China, other Asian regions, Europe, North America, and internationally. It operates through Finished Drugs, Bulk Products, and Functional Food and Others segments. The company provides NBP soft capsules and injections for acute ischemic stroke; Oulaining capsules and injections to treat mild to moderate memory and mental impairment; Enxi to treat adult idiopathic Parkinson's disease; Duomeisu for lymphoma, multiple myeloma, ovarian and breast cancers, and other malignant tumors; Jinyouli to prevent leucopenia and infection induced by chemotherapy; and Keaili for breast cancer. It also offers Shuluoke, Nuomoling, Weihong, and Xinweihong for various infections; Xuanning for hypertension; Encun to prevent atherosclerotic thrombosis events; Qixiao to treat upper respiratory tract infection; Linmeixin and Shuanglexin for diabetes; Gubang and Gubangjia to treat osteoporosis in postmenopausal women; and Gaoshunsong for arthritis, osteoarthritis, ankylosing spondylitis, frozen shoulder, bursuitis, tenosynovitis, acute gout, dysmenorrhea, toothache and postoperative pain, low back pain, sprain, strain, and other soft tissue injuries. In addition, the company provides Debixin for various ulcer; Qimaite for acute and chronic pains; antibiotics, vitamin C, and caffeine APIs; functional food products; and healthcare services. It has a strategic collaboration with AstraZeneca PLC to advance the discovery and development of novel oral candidates, with the potential to treat diseases across multiple indications and multiple therapies for obesity and type 2 diabetes. The company was formerly known as China Pharmaceutical Group Limited and changed its name to CSPC Pharmaceutical Group Limited in March 2013. CSPC Pharmaceutical Group Limited was incorporated in 1992 and is headquartered in Shijiazhuang, the People's Republic of China.

www.cspc.com.hk →

Dividend Safety

Assessment based on payout ratio, debt levels, profit margins, and dividend growth track record.

50

Borderline

Based on 4 fundamental factors

Share